CTOs on the Move

Allcells LLC

www.allcells.com

 
Allcells LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.allcells.com
  • 5858 Horton St Ste 360
    Emeryville, CA USA 94608
  • Phone: 510.450.3900

Executives

Name Title Contact Details

Similar Companies

Genentech

Genentech, Inc., is a biotechnology corporation which became a subsidiary of Roche in 2009.

Greenstone Biosciences

Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform to accelerate drug discovery.

Dechra

Dechra Pharmaceuticals PLC is a global leader in veterinary pharmaceuticals, dedicated exclusively to the veterinary market. Founded in 1997, the company has a rich history dating back to 1819. Dechra develops, manufactures, and markets high-quality pharmaceutical products and services aimed at improving animal health and welfare. It operates in 24 countries and distributes products in over 50 countries. The company offers a diverse portfolio of prescription-only veterinary medicines for companion animals and horses, focusing on areas such as endocrinology, dermatology, and critical care. Dechra also provides water-soluble antibiotics, poultry vaccines, and specialized diets. Its services division includes laboratories that support veterinary diagnostics. With a strong emphasis on understanding veterinarians needs, Dechra provides training and scientific resources to enhance animal care.

Five Prime Therapeutics

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company`s product candidates include FP-1039/GSK3052230, a protein therapeutic is in PhaseIb clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, an antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumors. It has collaboration and license agreements with GlaxoSmithKline LLC, Glaxo Group Limited, GSK-HGS, Pfizer Inc., and UCB Pharma S.A. The company was founded in 2001 and is headquartered in South San Francisco, California.

ChemDiv

ChemDiv Inc. (Chemical Diversity) is a global chemistry-driven contract research organization focused on identifying and delivering discovery opportunities and services for life science partners, and merging industrial and academic efforts to bring new